

**Supplementary Table 2.** Baseline clinical and radiological characteristics of patients with and without follow up imaging

	Patients with FU img. (N = 129)	Patients without FU img. (N = 102)	P value
Age (year)	77.0 ( $\pm$ 7.9)	77.9 ( $\pm$ 9.0)	0.43
Women	64 (49.6)	44 (43.1)	0.35
NOAC			0.84
Apixaban	20 (15.5)	16 (15.7)	
Dabigatran	36 (27.9)	26 (25.5)	
Rivaroxaban	73 (56.6)	60 (58.8)	
Concomitant platelet inhibition	13 (10.1)	11 (10.8)	> 0.99
CHA <sub>2</sub> DS <sub>2</sub> VASc score	5 (3–6)	4.5 (3–6)	0.59
HAS-BLED score	4 (3–4)	4 (3–4)	0.30
Medical history			
Ischemic stroke/TIA	60 (46.5)	47 (46.1)	> 0.99
Intracranial hemorrhage	3 (2.3)	2 (2.0)	> 0.99
Atrial fibrillation	119 (92.2)	90 (88.2)	0.37
Hypertension	106 (82.2)	87 (85.3)	0.59
Hyperlipidemia	47 (36.4)	34 (33.3)	0.68
Diabetes mellitus	44 (34.1)	25 (24.5)	0.15
Heart failure	34 (26.4)	19 (18.6)	0.21
Peripheral vascular disease	9 (7.0)	6 (5.9)	0.79
Renal function			0.20
GFR < 60 mL/min	53 (41.1)	32 (31.4)	
Creatinin level (mg/dL)	1.01 (0.87–1.30)	1.02 (0.84–1.28)	0.99
NIHSS at admission	4 (2–7)	3 (2–6)	0.36
Modified Rankin scale score			
Pre stroke	1 (0–2)	1 (0–2)	0.09
At admission	3 (1–4)	3 (2–4)	0.87
At discharge	2 (1–4)	2 (2–3)	0.57
At 3-months	2 (1–4)	3 (1–4)	0.33
mRS 0–2 at 3 months	66 (56.4)	44 (48.9)	0.33
In-hospital mortality	4 (3.1)	2 (2.0)	0.70
Time since last intake NOAC (hour)	9 (4.2–18.3)	8.3 (4.5–13.1)	0.35
Baseline ASPECTS	10 (9–10)	10 (9–10)	0.55
Infarct size			0.06
Small/medium	99 (76.7)	89 (87.3)	
Large anterior/posterior	30 (23.3)	13 (12.7)	